Compare WS & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WS | CMPS |
|---|---|---|
| Founded | 1955 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2023 | 2020 |
| Metric | WS | CMPS |
|---|---|---|
| Price | $39.72 | $10.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $23.75 |
| AVG Volume (30 Days) | 437.3K | ★ 2.5M |
| Earning Date | 10-06-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,443,800,000.00 | N/A |
| Revenue This Year | $11.55 | N/A |
| Revenue Next Year | $0.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.33 | N/A |
| 52 Week Low | $27.22 | $4.88 |
| 52 Week High | $49.17 | $15.87 |
| Indicator | WS | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 61.42 | 33.56 |
| Support Level | $38.01 | $10.66 |
| Resistance Level | $39.42 | $14.74 |
| Average True Range (ATR) | 1.92 | 0.57 |
| MACD | 0.34 | -0.11 |
| Stochastic Oscillator | 80.29 | 2.34 |
Worthington Steel Inc is a value-added metals processors with the ability to provide a diversified products and services that span a variety of end markets. It is a value-added processor of carbon flat-rolled steel and a producer of laser welded solutions and electrical steel laminations. It is one of the independent intermediate processors of carbon flat-rolled steel in the U.S. It occupy a niche in the steel industry by focusing on products requiring exact specifications. The company has one operating and reportable segment. It has presence in United States, Canada, Mexico, and Rest of world. The company has majority of sales from United States.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.